Gala Therapeutics-B (01672) has launched two Phase I studies for the treatment of obesity in the United States.

Zhiyin Finance APP news, Gilead Sciences-B (01672) announced that after obtaining approval from the U.S. Food and Drug Administration (FDA) for its New Drug Clinical Trial Application (IND), it has launched two Phase I studies in the United States for the treatment of obesity: a new generation of incretin receptor agonist peptide ASC36, administered once a month to once a quarter, and a subcutaneous fixed-dose combination (FDC) monthly injection ASC36_35FDC of ASC36 and GLP-1R/GIPR dual-target agonist peptide ASC35.